Anti-CD32B x Anti-CD79B Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD32B and anti-CD79B parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can regulate B-cell modulation. It is designed for the research of Immune diseases therapy.
FuncS; Promising therapeutic agent
FCGR2B; Fc fragment of IgG, low affinity IIb, receptor (CD32); FcγRIIB; CD32; FCG2; CD32B; FCGR2; IGFR2; low affinity immunoglobulin gamma Fc region receptor II-b; CDw32; fcRII-b; Fc gamma RIIb; fc-gamma-RIIb; fc-gamma RII-b; igG Fc receptor II-b; Fc fragment of IgG, low affinity II, receptor for (CD32); Fc fragment of IgG, low affinity IIb, receptor for (CD32)
CD79B; CD79b molecule, immunoglobulin-associated beta; Cluster of differentiation 79B; CD79b antigen; B29; IGB; AGM6; B-cell antigen receptor complex-associated protein beta chain; Ig-beta; B-cell-specific glycoprotein B29; immunoglobulin-associated B29 protein; CD79b antigen (immunoglobulin-associated beta); immunoglobulin-associated CD79 beta
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email